ロード中...
Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML
The therapeutic approach to Chronic Myeloid Leukemia (CML) has changed since the advent of the tyrosine kinase inhibitor (TKI) imatinib, which was then followed by the second generation TKIs dasatinib, nilotinib, and, finally, by ponatinib, a third-generation drug. At present, these therapeutic opti...
保存先:
| 出版年: | Int J Mol Sci |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
MDPI
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7352889/ https://ncbi.nlm.nih.gov/pubmed/32586039 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms21124469 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|